Safety of apixaban and rivaroxaban in patients with atrial fibrillation on hemodialysis
European Journal of Internal Medicine · 2024
DOI: 10.1016/j.ejim.2024.02.005 ↗Kurz gefasst
Leserbrief in der Zeitschrift European Journal of Internal Medicine, 2024. Verfasst von Hiroshi Ito. Beteiligte Einrichtung: Division of General Internal Medicine, Department of Internal Medicine, Tokyo Medical University Ibaraki Medical Center, 3-20-1 Chuo, Ami-machi, Inas…. Hauptthemen laut MEDLINE: Rivaroxaban, Atrial Fibrillation, Pyridones, Pyrazoles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 3 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of General Internal Medicine, Department of Internal Medicine, Tokyo Medical University Ibaraki Medical Center, 3-20-1 Chuo, Ami-machi, Inashiki-gun, Ibaraki, Japan 300-0395. Electronic address: itohirokan@yaho…
Zitieren
APA
Ito, H. (2024). Safety of apixaban and rivaroxaban in patients with atrial fibrillation on hemodialysis. European Journal of Internal Medicine. https://doi.org/10.1016/j.ejim.2024.02.005
Vancouver
Ito H. Safety of apixaban and rivaroxaban in patients with atrial fibrillation on hemodialysis. European Journal of Internal Medicine. 2024. doi:10.1016/j.ejim.2024.02.005
BibTeX
@article{Ito2024,
author = {Ito, Hiroshi},
title = {Safety of apixaban and rivaroxaban in patients with atrial fibrillation on hemodialysis},
journal = {European Journal of Internal Medicine},
year = {2024},
doi = {10.1016/j.ejim.2024.02.005}
}
EUVIMED